Xiao et al. use patient-derived rectal cancer organoids to identify that MEK inhibitors enhance radiation sensitivity by downregulating the DNA damage response protein RAD51. They find synergy with combined PARP inhibition in different preclinical models, thereby offering a promising regimen and potential future alternative to conventional chemoradiation in locally advanced rectal cancer.

Ein Forschungsteam aus Mannheim und Heidelberg erforscht eine medikamentöse Kombinationstherapie, die die Strahlentherapie bei Enddarmkrebs wirksamer machen kann.